Ajay Abad

Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Manmeet S. Ahluwalia, David A. Reardon, Ajay Abad et al. · Journal of Clinical Oncology · 2022 · 140 citations · Full text

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).

Josep Tabernero, Enrique Aranda, Alba Liliana Gil Gómez et al. · Journal of Clinical Oncology · 2010 · 39 citations

Surgical Oncology, Pathology, Maintenance Xelox-bev +17

Clinical and nutritional factors predictive of plasma lipid unsaturation deficiency in advanced liver cirrhosis: a logistic regression analysis.

Eduard Cabré, María Núñez, Ferrán Gónzalez‐Huix et al. · PubMed · 1993 · 26 citations

Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay

Stephen Shuford, Lindsay Lipinski, Ajay Abad et al. · Neuro-Oncology Advances · 2021 · 23 citations · Full text

SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.

Manmeet S. Ahluwalia, David A. Reardon, Ajay Abad et al. · Journal of Clinical Oncology · 2019 · 17 citations

Surgical Oncology, Cancer Management, Immunology +20